WILMINGTON, Mass., June 27, 2011 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.® (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that it has been added to the U.S. broad-market Russell 3000® Index. Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 24, 2011. The updated list can be found at www.russell.com/indexes.
